DeepMed Research

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

A Study to Learn About the Safety of PREVENAR 20 Vaccine in Infants Aged Between Two to Six Months

Active, not recruiting

Conditions: Pneumococcal Disease

Interventions: Biological: 20-valent Pneumococcal Conjugate Vaccine

First Posted Date: 2024-10-01

Last Posted Date: 2025-05-06

Lead Sponsor: Pfizer

Target Recruit Count: 1100

Registration Number: NCT06622109

Locations: 🇯🇵
Pfizer, Tokyo, Japan

A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine

Phase 3

Recruiting

Conditions: Migraine

Interventions: Drug: Rimegepant
Drug: Placebo

First Posted Date: 2024-09-27

Last Posted Date: 2025-05-06

Lead Sponsor: Pfizer

Target Recruit Count: 200

Registration Number: NCT06616194

Locations: 🇺🇸
Seattle Children's Hospital, Seattle, Washington, United States
🇨🇦
University Of Alberta Hospital, Edmonton, Alberta, Canada
🇨🇦
Stollery Children's Hospital, Edmonton, Alberta, Canada

and more 39 locations

Korean Post Marketing Surveillance for Comirnaty Injection (Bretovameran)

Active, not recruiting

Conditions: COVID-19 Vaccination

Interventions: Biological: Bretovameran

First Posted Date: 2024-09-26

Last Posted Date: 2025-05-13

Lead Sponsor: Pfizer

Target Recruit Count: 660

Registration Number: NCT06613984

Locations: 🇰🇷
Pfizer Korea, Seoul, Korea, Republic of

A Study to Learn About Somatrogon in Patients With Pediatric Growth Hormone Deficiency (p GHD) in India.

Recruiting

Conditions: Dwarfism, Pituitary

Interventions: Drug: Somatrogon

First Posted Date: 2024-09-19

Last Posted Date: 2025-04-18

Lead Sponsor: Pfizer

Target Recruit Count: 50

Registration Number: NCT06587035

Locations: 🇮🇳
Apollo Speciality Hospital, Madurai, Tamil NADU, India
🇮🇳
G Kuppuswamy Naidu Memorial Hospital, Coimbatore, Tamil NADU, India

A Study to Learn How Renal Impairment Affects the Pharmacokinetics of PF-07817883.

Phase 1

Completed

Conditions: COVID-19

Interventions: Drug: PF-07817883

First Posted Date: 2024-09-19

Last Posted Date: 2025-02-19

Lead Sponsor: Pfizer

Target Recruit Count: 16

Registration Number: NCT06586216

Locations: 🇺🇸
Prism Research LLC dba Nucleus Network, Saint Paul, Minnesota, United States
🇺🇸
Clinical Pharmacology of Miami, Miami, Florida, United States
🇺🇸
Genesis Clinical Research, LLC, Tampa, Florida, United States

A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Older Adults in Korea

Phase 3

Completed

Conditions: Respiratory Syncytial Virus

Interventions: Biological: RSVpreF Vaccine
Other: Placebo

First Posted Date: 2024-09-19

Last Posted Date: 2025-02-14

Lead Sponsor: Pfizer

Target Recruit Count: 377

Registration Number: NCT06593587

Locations: 🇰🇷
Inha University Hospital, Incheon, Incheon-gwangyeoksi [incheon], Korea, Republic of
🇰🇷
Jeonbuk National University Hospital, Jeonju-si, Jeonrabugdo, Korea, Republic of
🇰🇷
Chonnam National University Hospital, Gwangju-si, Kwangju-kwangyǒkshi, Korea, Republic of

and more 13 locations

A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma as Compared With Standard of Care Therapies

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Elranatamab
Drug: Standard of care

First Posted Date: 2024-09-19

Last Posted Date: 2025-05-20

Lead Sponsor: Pfizer

Target Recruit Count: 4

Registration Number: NCT06592222

Locations: 🇺🇸
Pfizer, New York, New York, United States

To Learn How Different Forms of Study Medicine Are Taken up Into the Blood and the Effect of Food on Study Medicine in Healthy Adults

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Ceftibuten
Drug: CTB-AVP in Tablet
Drug: Avibactam prodrug

First Posted Date: 2024-09-19

Last Posted Date: 2025-05-21

Lead Sponsor: Pfizer

Target Recruit Count: 13

Registration Number: NCT06593054

Locations: 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium

Korean Post Marketing Surveillance for ELREXFIO (Elranatamab).

Not yet recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Elranatamab

First Posted Date: 2024-09-03

Last Posted Date: 2025-05-20

Lead Sponsor: Pfizer

Target Recruit Count: 150

Registration Number: NCT06581848

Locations: 🇰🇷
Pfizer Korea, Seoul, Korea, Republic of

A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer

Phase 1

Active, not recruiting

Conditions: Non Small Cell Lung Cancer
Bladder Cancer
Renal Cell Carcinoma
Head and Neck Cancer
Melanoma
Colorectal Cancer

Interventions: Biological: PF-07921585
Biological: Sasanlimab

First Posted Date: 2024-08-30

Last Posted Date: 2025-04-20

Lead Sponsor: Pfizer

Target Recruit Count: 4

Registration Number: NCT06580938

Locations: 🇺🇸
Presbyterian/St. Lukes Medical Center, Denver, Colorado, United States
🇺🇸
Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
🇺🇸
Highlands Oncology Group, Springdale, Arkansas, United States

and more 3 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy